Cervical Cancer clinical trials in Kansas

11 actively recruiting cervical cancer trials at 8 sites across Kansas.

Data from ClinicalTrials.gov · last refreshed 2026-10-12

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07061977

Sites in Kansas:

University of Kansas Cancer Center — Kansas City, Kansas
University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06589804

Sites in Kansas:

HaysMed — Hays, Kansas
University of Kansas Cancer Center — Kansas City, Kansas
Lawrence Memorial Hospital — Lawrence, Kansas
The University of Kansas Cancer Center - Olathe — Olathe, Kansas
University of Kansas Cancer Center-Overland Park — Overland Park, Kansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a …

Sponsor: NRG Oncology

NCT ID: NCT07441681

Sites in Kansas:

University of Kansas Cancer Center — Kansas City, Kansas
University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
University of Kansas Health System Saint Francis Campus — Topeka, Kansas
University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Industry

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…

Sponsor: Bicara Therapeutics

NCT ID: NCT06788990

Sites in Kansas:

Site #0149 — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.

NCT ID: NCT06064877

Sites in Kansas:

University of Kansas Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT04671667

Sites in Kansas:

University of Kansas Cancer Center — Kansas City, Kansas
University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
University of Kansas Hospital-Indian Creek Campus — Overland Park, Kansas
University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cispl…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07195734

Sites in Kansas:

University of Kansas Cancer Center — Kansas City, Kansas
University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\[225Ac\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to e…

Sponsor: Aktis Oncology, Inc.

NCT ID: NCT07020117

Sites in Kansas:

University of Kansas — Westwood, Kansas

View on ClinicalTrials.gov →

Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca

NCT ID: NCT07124000

Sites in Kansas:

Research Site — Topeka, Kansas

View on ClinicalTrials.gov →

NA Recruiting Academic/Other

Implementing the NYU Electronic Patient Visit Assessment (ePVA) for Head and Neck Cancer In Rural and Urban Populations

The PI and the research team developed the New York University (NYU) Electronic Patient Visit Assessment (ePVA) for head and neck cancer (HNC) as a patient-reported outcome measure (PRO) for the early detection of uncontrolled symptoms. Th…

Sponsor: The University of Texas Health Science Center, Houston

NCT ID: NCT06030011

Sites in Kansas:

University of Kansas Cancer Center — Kansas City, Kansas

View on ClinicalTrials.gov →

Recruiting Academic/Other

NLit and Outcomes in HNC Survivor-Caregiver Dyads

The goal of this observational (cross-sectional) study is to better understand nutrition literacy in survivor-caregiver dyads and its impact on nutrition related outcomes and quality of life. We're interested in finding out how much they k…

Sponsor: University of Kansas Medical Center

NCT ID: NCT07021885

Sites in Kansas:

University of Kansas Medical Center — Kansas City, Kansas

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12